Brukinsa® was BeOne Medicines’s largest revenue line in fiscal 2025, bringing in $3.93B of $5.28B (74%).
| Product Name | FY 2020 | FY 2024 | FY 2025 |
|---|---|---|---|
| Brukinsa® | $2.64B | $3.93B | |
| Tevimbra® | $620.84M | $737.30M | |
| Tislelizumab | — | — | |
| Xgeva® | $224.40M | $305.98M | |
| Blincyto® | $74.33M | $104.22M | |
| Kyprolis® | $66.17M | $74.97M | |
| Other | $96.07M | $83.69M | |
| Pobevcy® | $53.51M | $47.40M | |
| Revlimid® | — | — | |
| Vidaza® | — | — | |
| Abraxane® | — | — | |
| Total | $3.78B | $5.28B |
BeOne Medicines brought in $5.28B from its seven revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 39.8% from $3.78B in fiscal 2024. Brukinsa® was the largest at $3.93B (74.4%), ahead of Tevimbra® at $737.30M (14.0%) and Xgeva® at $305.98M (5.8%). The other four revenue lines brought in $310.29M combined.
Compared with fiscal 2024, Brukinsa® grew fastest, up 48.6% to $3.93B. Every revenue line above 2% of revenue grew.
Product Revenue, Net was BeOne Medicines’s largest product and service line in fiscal 2025, bringing in $5.28B of $5.34B (99%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue, Net | $1.25B | $2.19B | $3.78B | $5.28B | ||||||
| Product | — | — | — | — | ||||||
| License Revenue | — | — | — | — | ||||||
| Other Revenue | — | $268.93M | $30.70M | — | ||||||
| Collaboration Revenue | $161.31M | — | — | — | ||||||
| Other | — | — | — | $20.24M | ||||||
| Reimbursement Of Research & Development Costs | — | — | — | — | ||||||
| Amgen Royalty Revenue | — | — | — | $40.73M | ||||||
| Research & Development Service Revenue | — | — | — | — | ||||||
| Total | $1.42B | $2.46B | $3.81B | $5.34B |
BeOne Medicines brought in $5.34B from its three product and service lines in fiscal 2025, the year ended December 31, 2025. BeOne Medicines regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $3.81B. Product Revenue, Net was the largest at $5.28B (98.9%), ahead of Amgen Royalty Revenue at $40.73M (0.8%) and Other at $20.24M (0.4%).
BeOne Medicines began breaking out Amgen Royalty Revenue in fiscal 2025, when it brought in $40.73M. BeOne Medicines stopped reporting Collaboration Revenue ($161.31M in fiscal 2022) and Other Revenue ($30.70M in fiscal 2024) as separate lines.
United States was BeOne Medicines’s largest region in fiscal 2025, bringing in $2.88B of $5.34B (54%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | $1.13B | $1.96B | $2.88B | |||||||
| U.S | $502.63M | — | — | — | |||||||
| Prc | $840.03M | $1.10B | $1.41B | $1.68B | |||||||
| China | — | — | — | — | |||||||
| Europe- Total Revenue | $63.26M | $202.01M | $362.63M | $611.37M | |||||||
| Other | $10.01M | $26.60M | $78.81M | $171.81M | |||||||
| All Other Countries Except China & The United States Of America | — | — | — | — | |||||||
| Total | $1.42B | $2.46B | $3.81B | $5.34B |
BeOne Medicines brought in $5.34B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 40.2% from $3.81B in fiscal 2024. United States was the largest at $2.88B (53.9%), ahead of Prc at $1.68B (31.4%) and Europe- Total Revenue at $611.37M (11.4%). The remaining region, Other, brought in $171.81M.
Compared with fiscal 2024, Other grew fastest, up 118.0% to $171.81M. Every region above 2% of revenue grew.
BeOne Medicines began breaking out United States in fiscal 2023, when it brought in $1.13B. BeOne Medicines stopped reporting U.S as a separate region after fiscal 2022, when it brought in $502.63M.
BeOne Medicines (ONC) reports its revenue by product name, by product and service and by geography. In fiscal 2025, Brukinsa® was its largest revenue line, bringing in $3.93B (74.4% of the total), followed by Tevimbra® at $737.30M (14.0%).
Brukinsa® was BeOne Medicines' largest revenue line in fiscal 2025, bringing in $3.93B, or 74.4% of the $5.28B total across its seven revenue lines.
Product Revenue, Net was BeOne Medicines' largest product and service line in fiscal 2025, bringing in $5.28B, or 98.9% of the $5.34B total across its three product and service lines.
United States was BeOne Medicines' largest region in fiscal 2025, bringing in $2.88B, or 53.9% of the $5.34B total across its four regions.
Among BeOne Medicines' revenue lines that make up at least 2% of revenue, Brukinsa® grew fastest in fiscal 2025, up 48.6% from $2.64B to $3.93B.
Every figure comes from BeOne Medicines' annual financial filings, as reported. Each line keeps the name BeOne Medicines gives it, and years follow its fiscal calendar.
BeOne Medicines' revenue by product name goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.